Exelixis, Inc. (EXEL): Price and Financial Metrics

Exelixis, Inc. (EXEL): $22.39

0.20 (+0.90%)

POWR Rating

Component Grades








Add EXEL to Watchlist
Sign Up

Industry: Biotech




#7 of 359

in industry

EXEL Price/Volume Stats

Current price $22.39 52-week high $22.80
Prev. close $22.19 52-week low $14.87
Day low $22.09 Volume 3,821,534
Day high $22.51 Avg. volume 2,716,753
50-day MA $21.29 Dividend yield N/A
200-day MA $18.96 Market Cap 7.13B

EXEL Stock Price Chart Interactive Chart >


  • EXEL scores best on the Quality dimension, with a Quality rank ahead of 96.38% of US stocks.
  • The strongest trend for EXEL is in Stability, which has been heading up over the past 177 days.
  • EXEL ranks lowest in Momentum; there it ranks in the 3rd percentile.

EXEL Stock Summary

  • With a price/earnings ratio of 41.64, EXELIXIS INC P/E ratio is greater than that of about 85.3% of stocks in our set with positive earnings.
  • Of note is the ratio of EXELIXIS INC's sales and general administrative expense to its total operating expenses; just 15.52% of US stocks have a lower such ratio.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.22 for EXELIXIS INC; that's greater than it is for only 14.21% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to EXELIXIS INC are BCDA, GSIT, SABS, MRKR, and SMR.
  • EXEL's SEC filings can be seen here. And to visit EXELIXIS INC's official web site, go to www.exelixis.com.

EXEL Valuation Summary

  • EXEL's price/sales ratio is 4; this is 110.53% higher than that of the median Healthcare stock.
  • EXEL's price/sales ratio has moved down 6.7 over the prior 243 months.

Below are key valuation metrics over time for EXEL.

Stock Date P/S P/B P/E EV/EBIT
EXEL 2023-09-22 4.0 2.7 41.6 31.4
EXEL 2023-09-21 4.0 2.7 41.8 31.5
EXEL 2023-09-20 4.0 2.7 41.7 31.4
EXEL 2023-09-19 4.0 2.7 41.5 31.3
EXEL 2023-09-18 4.0 2.7 41.4 31.2
EXEL 2023-09-15 4.1 2.7 42.3 31.9

EXEL Growth Metrics

    Its year over year price growth rate is now at -14.86%.
  • The year over year net income to common stockholders growth rate now stands at 360.14%.
  • Its 4 year net income to common stockholders growth rate is now at 8238.51%.
Over the past 15 months, EXEL's revenue has gone up $357,180,000.

The table below shows EXEL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 1,611.062 362.614 182.282
2022-09-30 1,638.285 385.372 307.621
2022-06-30 1,554.97 358.608 272.615
2022-03-31 1,520.72 508.979 298.035
2021-12-31 1,434.97 400.804 231.063
2021-09-30 1,253.882 337.645 164.285

EXEL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EXEL has a Quality Grade of B, ranking ahead of 93.02% of graded US stocks.
  • EXEL's asset turnover comes in at 0.549 -- ranking 297th of 563 Business Services stocks.
  • BBSI, QNST, and ROL are the stocks whose asset turnover ratios are most correlated with EXEL.

The table below shows EXEL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.549 0.961 0.128
2021-06-30 0.525 0.960 0.071
2021-03-31 0.486 0.961 0.045
2020-12-31 0.479 0.963 0.088
2020-09-30 0.479 0.961 0.129
2020-06-30 0.520 0.963 0.248

EXEL Price Target

For more insight on analysts targets of EXEL, see our EXEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $31.77 Average Broker Recommendation 1.46 (Moderate Buy)

Exelixis, Inc. (EXEL) Company Bio

Exelixis is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. The company was founded in 1994 and is based in San Francisco, California.

EXEL Latest News Stream

Event/Time News Detail
Loading, please wait...

EXEL Latest Social Stream

Loading social stream, please wait...

View Full EXEL Social Stream

Latest EXEL News From Around the Web

Below are the latest news stories about EXELIXIS INC that investors may wish to consider to help them evaluate EXEL as an investment opportunity.

3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall

Even with higher for longer interest rates, drug discovery moves on.

Chris Markoch on InvestorPlace | September 20, 2023

GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related Anemia

GSK's Ojjaara (momelotinib) is the first and the only drug approved to treat myelofibrosis patients with anemia in the United States.

Yahoo | September 18, 2023

4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

Wall Street has vacillated between bull and bear markets, with the growth-focused Nasdaq Composite (NASDAQINDEX: ^IXIC) being whipsawed more than any other major index. During the 2022 bear market, the innovation-fueled Nasdaq shed up to 38% of its value and ended the year lower by 33%. Through the first eight months and change of 2023, the Nasdaq Composite is higher by nearly 32%.

Yahoo | September 16, 2023

2 Top Biotech Stocks Defying the Bear Market

Let's discuss why Exelixis and Axsome are solid picks for investors. Exelixis is an oncology specialist best known for its blockbuster cancer drug Cabometyx. For instance, Exelixis recently settled a patent litigation lawsuit with Teva Pharmaceuticals that will stop the generic drugmaker from launching Cabometyx's generics before 2031.

Yahoo | September 15, 2023

Exelixis (EXEL) Gets Rights for Tumor Candidate From Insilico

Exelixis (EXEL) enters into a license agreement with Insilico Medicine for ISM3091, a potentially best-in-class USP1 inhibitor.

Yahoo | September 13, 2023

Read More 'EXEL' Stories Here

EXEL Price Returns

1-mo -0.04%
3-mo 17.16%
6-mo 15.35%
1-year 38.30%
3-year -5.65%
5-year 26.35%
YTD 39.59%
2022 -12.25%
2021 -8.92%
2020 13.90%
2019 -10.42%
2018 -35.30%

Continue Researching EXEL

Here are a few links from around the web to help you further your research on Exelixis Inc's stock as an investment opportunity:

Exelixis Inc (EXEL) Stock Price | Nasdaq
Exelixis Inc (EXEL) Stock Quote, History and News - Yahoo Finance
Exelixis Inc (EXEL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!